Stay updated with breaking news from Acticor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company specialized in developing innovative treatments for cardiovascular emergencies
Regulatory News: Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announced today the results of
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies
pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority (AMF Autorité des Marchés Financiers) Regulatory
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces that the U.S Food and Drug